AOD-9604 5mg

Overview

AOD-9604 5 mg is a synthetic hexadecapeptide derived from the C-terminus of human growth hormone (hGH), supplied by
Peptide Tech at ≥ 99% purity (HPLC/MS verified) for in-vitro, cellular, and biochemical research use only (RUO). In controlled lab models, AOD-9604 is used to interrogate lipid-metabolism pathways, β-adrenergic–linked signaling, and peptide stability for analytical method development.

Specifications

CAS Number	221231-10-3
Chemical Name	AOD-9604 (hGH C-terminal analog)
PubChem CID	CID 71300630
Molecular Formula	C78H123N23O23S2
Molecular Weight	≈ 1,815.1 g/mol
Sequence	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (disulfide Cys7↔Cys14)
Physical Appearance	White to off-white lyophilized powder
Container	3 mL glass vial (5 mg net content)
Purity	≥ 99% (verified by HPLC & MS; third-party tested)
Solubility	Soluble in sterile water or compatible aqueous buffer; gently swirl to dissolve; 0.22 µm filter-sterilize if required

Molecular Structure

Why Peptide Tech

• Same-Day Shipping
• GMP-Aligned Lyophilized Peptides
• USA Made
• 24/7 Support
• Price Match Guarantee
• Batch Tracking with QR Code Verification
• 3rd-Party USA Lab Testing — purity, quantity, endotoxin
• Cold-Chain Shipping — Always (no paid upgrade)
• Worldwide Shipping
• All Major Payments Accepted
• Text & Email Order Updates
• 2-Day FedEx/UPS Shipping Standard
• Cheapest Overnight Rates
• Largest Variety of Peptides & Bioregulators

Storage & Handling

• Lyophilized (unopened): Store at ≤ −20 °C, protected from light and moisture. For long-term archival, ≤ −80 °C is recommended.
• After reconstitution: Aliquot immediately to avoid repeated freeze–thaw; store at ≤ −80 °C (≤ −20 °C acceptable for short-term studies).
• General notes: Allow the vial to reach room temperature before opening to minimize condensation. Use sterile technique and compatible buffers; avoid strong acids/bases.
• Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.

Potential Applications in Research

Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.

• Adipocyte lipolysis/lipogenesis models: Quantify glycerol/FFA release and lipogenic markers in vitro or ex vivo.
  Endocrinology, 2001.
• β-Adrenergic pathway interrogation: Explore β₃-AR–related mechanisms in rodent and cell systems.
  Endocrinology, 2001.
• Hepatocyte/adipocyte enzyme studies: Evaluate effects on lipogenic enzymes (e.g., ACC) and metabolic readouts.
  Biochem Mol Biol Int, 1993.
• Comparative peptide pharmacology: Contrast AOD-9604 with related hGH fragments in dose/response and stability workflows.
  Am J Physiol Endocrinol Metab, 2000.
• Pathway-level context (review): Situate findings within broader anti-obesity targets for hypothesis generation.
  Clin Pharmacol Ther, 2010.

Citations (PubMed)

• Heffernan, M. A., et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β₃-AR knock-out mice.” Endocrinology 142(12), 2001, 5182–5189.
  PubMed
• Heffernan, M. A., Jiang, W. J., Thorburn, A. W., Ng, F. M. “Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism.” Am J Physiol Endocrinol Metab 279(3), 2000, E501–E507.
  PubMed
• Wu, Z., Ng, F. M. “Antilipogenic action of synthetic C-terminal sequence 177–191 of human growth hormone.” Biochem Mol Biol Int 30(1), 1993, 187–196.
  PubMed
• Valentino, M. A., Lin, J., Waldman, S. A. “Central and peripheral molecular targets for anti-obesity pharmacotherapy.” Clin Pharmacol Ther 87(6), 2010, 652–662.
  PubMed

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.